Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Dexamethasone The Next HCQ For Indian Pharma?

Zydus Cadila, Wockhardt, Cadila, Cipla Could Gain

Executive Summary

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations

You may also be interested in...



Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe

Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.

Coronavirus Update: 'Positive News' Imminent From Oxford and AstraZeneca Vaccine

More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel